pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
330
stories
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
6d
Biotech initiatives pick up as more regions race to become hubs
biopharma dive
7d
STAT+: Eli Lilly targets booming black market for retatrutide
stat
7d
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
7d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
8d
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
8d
Behind the bell: Gearing up to go public
biospace
8d
Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China
raps
8d
STAT+: Cancer patients face longer wait times to begin treatment, according to new study
stat
8d
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
8d
STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
stat
9d
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
9d
STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
stat
9d
CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
fiercebiotech
9d
Opinion: Trump says his executive order should restore trust in vaccines. It does the exact opposite
stat
9d
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
biopharma dive
9d
Building Resilience for the Future of Biopharma Innovation
fiercebiotech
9d
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
biopharma dive
9d
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
fiercebiotech
9d
Epicrispr, Infinimmune snag combined $165M in VC cash
biospace
9d
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
biospace
9d
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
biospace
10d
Epicrispr raises $90M to rewrite treatment of rare muscle disease
fiercebiotech
10d
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
10d
BMS picks Texas for new $2.3B manufacturing campus
biospace
10d
Regeneron backs $75M series A for antibody upstart Infinimmune
fiercebiotech
10d
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
10d
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
11d
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
11d
Opinion: We prepared for Ebola — but not this Ebola
stat
← prev
page 2 of 11
next →
